Cala Health, Inc., a San Francisco, CA-based bioelectronic medicine company developing wearable therapies for chronic disease has raised $50 million in Series C funding. New investors in the Series C funding round include Novartis, Baird Capital, LifeSci Venture Partners, TriVentures, and others. All existing investors participated in the round, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Lux Capital, Lightstone Ventures, Action Potential Venture Capital, dRx Capital, and GV.
Founded in 2014, Carla Health is transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health’s wearable therapy is essential tremor, a disease experienced by more than seven million people and characterized by severe hand tremors.
Therapeutic Pipeline: Essential Tremors
Essential tremors (ET) is marked by hand tremors that make it difficult, if not impossible, to perform daily activities like eating, drinking, and writing. Cala Health is working on a solution that retunes the nervous system in order to relieve the symptoms of ET. Cala Health is striving to put patients in control of their tremor — without the need for invasive brain surgery or drugs. Cala Health supports the International Essential Tremor Foundation (IETF) and works to connect people living with essential tremor to new therapies. New therapies are under development in neurology, cardiology, and psychiatry.
Cala Health is preparing for the limited release of the prescription Cala Trio therapy, including an innovative commercial strategy that delivers prescription therapy with the convenience of consumer electronics by serving the patients as a direct distributor. The company recently announced completing enrollment in the largest therapeutic study ever conducted in essential tremor in the US, the landmark PROspective study for SymPtomatic relief of Essential tremor with Cala Therapy (PROSPECT). Cala Health will use the funds to introduce Cala TrioTM, a breakthrough therapy for hand tremors in people with essential tremor, to the market, as well as expand it’s therapeutic pipeline.
“We are delighted to work with such a strong team of investors and advisors who share our vision for the future of bioelectronic medicines. This financing follows exciting momentum from the past year, including receiving De Novo clearance from the Food and Drug Administration for our therapy for essential tremor and announcing a licensing agreement and ongoing collaboration with Partners Healthcare Innovation and its affiliate, Massachusetts General Hospital,” said Kate Rosenbluth, Ph.D., Founder and CEO, Cala Health.